The N-terminal Domain of Hepatocyte Growth Factor Inhibits the Angiogenic Behavior of Endothelial Cells Independently from Binding to the c-met Receptor*
暂无分享,去创建一个
Patrick England | Shunli Ding | C. Demerens | Tatyana Merkulova-Rainon | Corinne Demerens | Gérard Tobelem | G. Tobelem | P. England | Shunli Ding | Tatyana Merkulova-Rainon
[1] J. Folkman,et al. Kringle Domains of Human Angiostatin , 1996, The Journal of Biological Chemistry.
[2] K. Matsumoto,et al. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. , 2000, Cancer research.
[3] L. Pannell,et al. Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. , 1997, The Biochemical journal.
[4] D. Carey,et al. Syndecans: multifunctional cell-surface co-receptors. , 1997, The Biochemical journal.
[5] T. Ishiwata,et al. Hepatocyte growth factor (HGF), HGF activator, and c-Met in synovial tissues in rheumatoid arthritis and osteoarthritis. , 2001, The Journal of rheumatology.
[6] B. Toole,et al. Biotinylated hyaluronan as a probe for detection of binding proteins in cells and tissues. , 1995, BioTechniques.
[7] G. Camussi,et al. In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[8] K. Matsumoto,et al. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] M. Braun,et al. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[10] M. Gerritsen,et al. Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels. , 1999, The American journal of pathology.
[11] M. Ueda,et al. Hepatocyte growth factor and its variant with a deletion of five amino acids are distinguishable in their biological activity and tertiary structure. , 1994, Biochemical and biophysical research communications.
[12] Y. Taniyama,et al. Therapeutic Angiogenesis Induced by Human Hepatocyte Growth Factor Gene in Rat Diabetic Hind Limb Ischemia Model: Molecular Mechanisms of Delayed Angiogenesis in Diabetes , 2001, Circulation.
[13] L. Presta,et al. Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-Met receptor. , 1994, Protein engineering.
[14] D C Rees,et al. Heparin Structure and Interactions with Basic Fibroblast Growth Factor , 1996, Science.
[15] L. Aiello,et al. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth. , 2000, Investigative ophthalmology & visual science.
[16] M. Lyon,et al. The Mode of Action of Heparan and Dermatan Sulfates in the Regulation of Hepatocyte Growth Factor/Scatter Factor* , 2002, The Journal of Biological Chemistry.
[17] Tae-Hee Lee,et al. Prothrombin Kringle-2 Domain Has a Growth Inhibitory Activity against Basic Fibroblast Growth Factor-stimulated Capillary Endothelial Cells* , 1998, The Journal of Biological Chemistry.
[18] J. Rubin,et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.
[19] B. Keyt,et al. Solution structure of the heparin-binding domain of vascular endothelial growth factor. , 1998, Structure.
[20] M. Aoki,et al. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model , 2000, Gene Therapy.
[21] G. Merlino,et al. NK1, a Natural Splice Variant of Hepatocyte Growth Factor/Scatter Factor, Is a Partial Agonist In Vivo , 1998, Molecular and Cellular Biology.
[22] G. Merlino,et al. Disassociation of Met-Mediated Biological Responses In Vivo: the Natural Hepatocyte Growth Factor/Scatter Factor Splice Variant NK2 Antagonizes Growth but Facilitates Metastasis , 2000, Molecular and Cellular Biology.
[23] W. Birchmeier,et al. A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[24] P. Wingfield,et al. The solution structure of the N-terminal domain of hepatocyte growth factor reveals a potential heparin-binding site. , 1998, Structure.
[25] A. Chaffotte,et al. Proteasome Inhibition in Glyoxal-treated Fibroblasts and Resistance of Glycated Glucose-6-phosphate Dehydrogenase to 20 S Proteasome Degradation in Vitro * , 2001, The Journal of Biological Chemistry.
[26] C. Bucana,et al. Regulation of distinct steps of angiogenesis by different angiogenic molecules. , 1998, International journal of oncology.
[27] Kazuho Ikeo,et al. Different evolutionary histories of kringle and protease domains in serine proteases: A typical example of domain evolution , 1995, Journal of Molecular Evolution.
[28] T L Blundell,et al. Crystal structures of NK1–heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor , 2001, The EMBO journal.
[29] A. Yajima,et al. Tumor angiogenesis, hepatocyte growth factor, and c‐Met expression in endometrial carcinoma , 1998 .
[30] L. Naldini,et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth , 1992, The Journal of cell biology.
[31] K. Miyazawa,et al. Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. , 1993, The Journal of biological chemistry.
[32] B. Davidson,et al. The FASEB Journal express article 10.1096/fj.01-0421fje. Published online November 29, 2001. , 2022 .
[33] P. Wingfield,et al. Dissociation of Heparan Sulfate and Receptor Binding Domains of Hepatocyte Growth Factor Reveals That Heparan Sulfate-c-Met Interaction Facilitates Signaling* , 2001, The Journal of Biological Chemistry.
[34] O. Reizes,et al. Cell Surface Heparan Sulfate Proteoglycans: Selective Regulators of Ligand-Receptor Encounters* , 2000, The Journal of Biological Chemistry.
[35] E. Jaffe,et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.
[36] J. Turnbull,et al. Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides , 1999, Current Biology.
[37] P. Godowski,et al. Structure‐function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. , 1992, The EMBO journal.
[38] J. Isner,et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. , 1998, Circulation.
[39] W. Birchmeier,et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. , 1992, The EMBO journal.
[40] Michael Stoker,et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility , 1987, Nature.
[41] K. Tashiro,et al. Molecular cloning and expression of human hepatocyte growth factor , 1989, Nature.
[42] Toshikazu Nakamura,et al. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor , 1997, FEBS letters.
[43] Y. Taniyama,et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease , 2001, Gene Therapy.
[44] P. Godowski,et al. Generation and characterization of a competitive antagonist of human hepatocyte growth factor, HGF/NK1. , 1993, The Journal of biological chemistry.
[45] V. Trieu,et al. Apolipoprotein(a), a link between atherosclerosis and tumor angiogenesis. , 1999, Biochemical and biophysical research communications.
[46] J. Schlessinger,et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. , 2000, Molecular cell.
[47] M. Ishihara,et al. Structural features in heparin that interact with VEGF165 and modulate its biological activity. , 1999, Glycobiology.
[48] Lars Holmgren,et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.
[49] M. Hendrix,et al. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). , 1998, The American journal of pathology.
[50] M. Westphal,et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis , 1999, International journal of cancer.
[51] M. Llinás,et al. Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth* , 1997, The Journal of Biological Chemistry.
[52] David F. Burke,et al. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin , 2000, Nature.
[53] T. Nakamura,et al. Hepatocyte Growth Factor/Scatter Factor Binds with High Affinity to Dermatan Sulfate* , 1998, The Journal of Biological Chemistry.
[54] M. Mori,et al. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine , 2002, Oncogene.
[55] T. Nakamura,et al. Hairpin loop and second kringle domain are essential sites for heparin binding and biological activity of hepatocyte growth factor. , 1994, The Journal of biological chemistry.